Be the global leader of T cell cancer immunotherapy
Advisory Team
  • Mark M. Davis
    Mark M. Davis
    Co-Chair, SAB
    Director, Stanford Institute for Immunity;

    Member, American Academy of Sciences;

    Member, Royal Society of the UK;

    Dr. Mark M. Davis is the Burt and Marion Avery Family Professor of Immunology at Stanford University. Dr. Davis has been an investigator at the Howard Hughes Medical Institute since 1987. He is also a member of National Academy of Sciences, American Academy of Arts and Sciences, and National Academy of Medicine. Since his ground-breaking cloning of T cell antigen receptor genes (TCR) in 1984, Dr. Davis has been a pioneer and leader the field of molecular immunology. Specifically, by pushing the boundaries of knowledge in multiple areas, such as antigen receptor recognition, thymic selection, and B cell terminal differentiation, his discoveries shaped our understanding of self versus nonself discrimination, the most fundamental question in adaptive immunity. In addition, the Davis lab is the acclaimed source of technology integration and innovation. The application of protein chemistry, biophysics, and live cell imaging in the Davis lab have made the study of T cell recognition the most advanced and quantitative of any system of cell-cell recognition in biology. Technologies developed in the Davis lab, such as peptide-MHC tetramers, have become standard tools in basic and clinical immunology studies. In 2004, Dr. Davis became the founding director of Stanford Institute for Immunity, Transplantation and Infection and an advocate of human immunology. He then changed his lab’s focus away from basic immunology to studies of the human immune system. Here, he has also had a tremendous impact, developing more advanced ways to monitor immunity and responses clinically, and integrating repertoire sequencing, single cell genomics and proteomics technologies to challenge immunological dogma and the power of human work to contribute to basic immunological principals. His innovations and dedication have opened a new chapter in human immunology and translational medicine.

  • Xiao-Fan Wang
    Xiao-Fan Wang
    Co-Chair, SAB
    Cooke Professor of Cancer Research, Duke University School of Medicine;

    Foreign Member, Chinese Academy of Science.

    Prof. Wang has made important contributions to cancer-related fields such as cell signal transduction, DNA damage and repair, and tumor microenvironment. He was the first to clone the TGF-β type II and type III receptors, which was an important discovery and had profound impact on the subsequent research of TGF-β. He also determined several important regulatory factors and mechanisms of the TGF-β pathway, which are critical to current understanding of the tumor microenvironment. Prof. Wang published more than 20 papers in high profile journals including Cell, Nature, Science, Genes and Development, P.N.A.S.

    Since 2006, he has served as the deputy editor-in-chief of the Journal of Biological Chemistry. During his tenure as editor-in-chief, he introduced dozens of Chinese science and technology leaders to advocate for the impact of Chinese scientists to the global community. Since 2007, he served as a member of the Overseas Expert Advisory Committee of China. In 2010, he was appointed as a member of the scientific board of the Ministry of Science and Technology and has participated in many reforms of Chinese science policies. In order to help establish an academic evaluation system in China, Prof. Wang organized a team of experts from more than 10 top life science research institutes including Chinese Academy of Sciences, Tsinghua University, Peking University, Zhejiang University Life, and other universities.

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Product and Cinical trial
News and Media

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer